JP2014511891A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511891A5
JP2014511891A5 JP2014505610A JP2014505610A JP2014511891A5 JP 2014511891 A5 JP2014511891 A5 JP 2014511891A5 JP 2014505610 A JP2014505610 A JP 2014505610A JP 2014505610 A JP2014505610 A JP 2014505610A JP 2014511891 A5 JP2014511891 A5 JP 2014511891A5
Authority
JP
Japan
Prior art keywords
compound
salt
methyl
pharmaceutically acceptable
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505610A
Other languages
English (en)
Japanese (ja)
Other versions
JP5840763B2 (ja
JP2014511891A (ja
Filing date
Publication date
Priority claimed from GB201106743A external-priority patent/GB201106743D0/en
Application filed filed Critical
Publication of JP2014511891A publication Critical patent/JP2014511891A/ja
Publication of JP2014511891A5 publication Critical patent/JP2014511891A5/ja
Application granted granted Critical
Publication of JP5840763B2 publication Critical patent/JP5840763B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505610A 2011-04-21 2012-04-19 ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体 Expired - Fee Related JP5840763B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1106743.6 2011-04-21
GB201106743A GB201106743D0 (en) 2011-04-21 2011-04-21 Novel compounds
PCT/EP2012/057111 WO2012143413A1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
JP2014511891A JP2014511891A (ja) 2014-05-19
JP2014511891A5 true JP2014511891A5 (https=) 2015-04-30
JP5840763B2 JP5840763B2 (ja) 2016-01-06

Family

ID=44147335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505610A Expired - Fee Related JP5840763B2 (ja) 2011-04-21 2012-04-19 ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体

Country Status (16)

Country Link
US (1) US9029395B2 (https=)
EP (1) EP2699550B1 (https=)
JP (1) JP5840763B2 (https=)
KR (1) KR101896599B1 (https=)
CN (1) CN103619820B (https=)
AU (1) AU2012244759B2 (https=)
BR (1) BR112013026834A2 (https=)
CA (1) CA2832763C (https=)
EA (1) EA022341B1 (https=)
ES (1) ES2544302T3 (https=)
GB (1) GB201106743D0 (https=)
IL (1) IL228707A (https=)
MX (1) MX338515B (https=)
SG (1) SG194469A1 (https=)
WO (1) WO2012143413A1 (https=)
ZA (1) ZA201307645B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
HUE043568T2 (hu) 2013-03-14 2019-08-28 Glaxosmithkline Ip No 2 Ltd 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規の置換された二環式化合物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規キナゾリノン
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EP3105232B1 (en) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
JP6759514B2 (ja) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブNuevolution A/S ブロモドメインに対して活性な化合物
BR112017004580A2 (pt) 2014-09-12 2018-01-23 GlaxoSmithKline Intellectual Property composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Betタンパク質阻害剤として用いるための三環式複素環化合物
CA2960090A1 (en) * 2014-10-02 2016-04-07 Glaxosmithkline Intellectual Property (No.2) Limited Compound
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
WO2018111805A1 (en) 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
WO2010113498A1 (ja) * 2009-03-31 2010-10-07 興和株式会社 テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
WO2011054851A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013033268A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same

Similar Documents

Publication Publication Date Title
JP2014511891A5 (https=)
JP2014511892A5 (https=)
JP2016503797A5 (https=)
JP2013537203A5 (https=)
JP2013519675A5 (https=)
JP2015505296A5 (https=)
JP2013510120A5 (https=)
JP2016530259A5 (https=)
JP2016515561A5 (https=)
JP2011529054A5 (https=)
JP2016506962A5 (https=)
JP2013508279A5 (https=)
JP2013543896A5 (https=)
JP2013542261A5 (https=)
JP2015501833A5 (https=)
JP2013509429A5 (https=)
JP2020532547A5 (https=)
RU2016134751A (ru) Соединения
JP2016531126A5 (https=)
JP2016506961A5 (https=)
JP2017504635A5 (https=)
JP2020502047A5 (https=)
JP2019501130A5 (https=)
JP2015516427A5 (https=)
JP2015521195A5 (https=)